Lansdowne Partners

Vienna-based Ribbon aims to reduce a bottleneck in the development of biologics

Oxford diagnostics play raises $85M series C to get first regulatory submission

Start-up is advancing multiple platforms and programs through a hub-and-spoke model

Plus Merck brings tau mAb to clinic, ethris and Ribbon Biolabs raise venture rounds, and more 

Plus: LianBio’s infigratinib approved for pilot, Takeda, Arcutis, Sorriso and more